全球纖維腺瘤市場：按類型、診斷和治療、最終用戶和地區進行預測（~2032年）

纖維腺瘤市場規模預計將從 2023 年的 7.1 億美元和 2024 年的 7.7 億美元增長到 2032 年的 13.4 億美元，預計在預測期內複合年增長率為 6.36%。

女性纖維腺瘤盛行率的上升以及透過公共教育活動提高對纖維腺瘤的認識是推動纖維水腫市場成長的關鍵因素。

旨在提高對纖維腺瘤認識的公共教育活動是纖維腺瘤市場成長的關鍵因素。公共教育活動對於讓女性瞭解纖維腺瘤的徵兆和症狀至關重要。這種意識的提高促使女性定期進行乳房檢查和篩檢，並促進積極的尋求健康行為。纖維腺瘤的及時干預和適當管理取決於早期發現。此外，公共教育活動可以幫助消除對乳房腫塊的誤解，並減少經常伴隨此類發現的焦慮和恐懼。

此外，纖維腺瘤市場的擴張也很大程度受到診斷方法進步的影響。診斷工具的進步顯著提高了檢測準確性，這對於及時、適當的醫療幹預至關重要。準確識別纖維腺瘤至關重要。改進的診斷技術使醫療專業人員能夠更早地識別纖維腺瘤。早期識別對於及時實施有針對性的治療策略、減少併發症的可能性並改善患者的治療效果至關重要。透過磁振造影 (MRI) 和超音波等非侵入性影像技術的引入和改進，纖維腺瘤的診斷方法發生了變化。

該報告調查了全球纖維腺瘤市場，並提供市場定義和概述、影響市場成長和市場機會的因素分析、市場規模趨勢和預測、按各個區隔市場/地區/主要國家進行區隔，總結了競爭環境、主要公司概況， ETC。

目錄

第1章 內容提要

第2章 市場概況

第3章 研究方法

第4章 市場動態

• 概述
• 促進因素
  • 透過公共教育活動提高意識
  • 診斷技術的發展和改進以準確識別纖維腺瘤
  • 女性纖維腺瘤盛行率增加
• 抑制因素
  • 治療纖維腺瘤的費用較高
• 機會
  • 纖維腺瘤微創手術、藥物治療等新療法研究
  • 越來越多採用微創手術治療纖維腺瘤
• 任務
  • 纖維腺瘤不會危及生命
• COVID-19 影響分析

第5章 市場因素分析

• 價值鏈分析
• 波特五力分析

第六章全球纖維腺瘤市場：依類型

• 單純性纖維腺瘤
• 複雜性纖維腺瘤

第七章全球纖維腺瘤市場：依診斷及治療

• 診斷
  • 超音波掃瞄
  • 乳腺攝影
  • 活檢
• 治療
  • 冷凍消融
  • 高強度聚焦超音波（HIFU）
  • 乳房切除手術
  • 藥品

第八章全球纖維腺瘤市場：依最終用戶分類

• 醫院/診所
• 診斷中心
• 其他

第九章全球纖維腺瘤市場：按地區

• 概述
• 北美
• 歐洲
• 亞太地區
• 其他地區

第10章 競爭格局

• 比賽儀表板
• 市場份額分析
• 上市公司股票概覽
• 主要發展和成長策略

第11章 公司簡介

• GE HEALTHCARE
• KONINKLIJKE PHILIPS N.V.
• SHIMADZU CORPORATION
• SIEMENS HEALTHINEERS
• CANON MEDICAL SYSTEMS CORPORATION
• DILON TECHNOLOGIES
• PFIZER, INC
• ICECURE MEDICAL
• ALPINION MEDICAL SYSTEMS
• FUJIFILM HOLDINGS CORPORATION

第12章 附錄

• 參考
• 相關報導

Global Fibroadenoma Market Research Report Information by Type (Simple Fibroadenoma and Complex Fibroadenoma), by Diagnosis & Treatment (Diagnosis [Ultrasound Scan, Mammography, and Biopsy] and Treatment [Cryoablation, High Intensity Focused Ultrasound (HIFU), Lumpectomy, and Drugs {Dydrogesterone, Medroxyprogesterone, Selective Estrogen Receptor Modulators, and Others}], by End User (Hospital and Clinics, Diagnostic Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market overview

In 2023, the fibroadenoma market was estimated to be worth USD 0.71 billion. During the forecast period (2024-2032), the Fibroadenoma Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.36%, increasing from USD 0.77 billion in 2024 to USD 1.34 billion by 2032.

Rising incidences of fibroadenoma among women and increased awareness of fibroadenoma through public education campaigns are the primary factors propelling the growth of the fibroedema market.

Public education campaigns that aim to raise awareness of fibroadenoma are a significant factor in the growth of the fibroadenoma market. Public education campaigns are essential for informing women about the signs and symptoms of fibroadenoma. This increased awareness motivates women to undertake routine breast examinations and screenings and promotes proactive health-seeking behavior. The expeditious intervention and appropriate management of fibroadenomas are contingent upon early detection. Additionally, public education campaigns assist in the debunking of myths and misconceptions regarding breast lumps, thereby reducing the anxiety and dread that are often associated with such discoveries.

Additionally, the expansion of the fibroadenoma market is significantly influenced by the advancement of diagnostic methods. The precision of detection has been substantially improved by advancements in diagnostic tools, which are essential for timely and appropriate medical intervention. Accurate identification of fibroadenomas is essential. Healthcare professionals can identify fibroadenomas at an earlier stage with the assistance of improved diagnostic techniques. There is a critical need for early identification in order to implement treatment strategies that are timely and targeted, reduce the likelihood of complications, and improve patient outcomes. The diagnostic approach to fibroadenomas has been transformed by the introduction and refinement of non-invasive imaging technologies, including magnetic resonance imaging (MRI) and ultrasound.

Market segment insights

The Fibroadenoma Market is segmented into simple and complex fibroadenoma based on type.

The fibroadenoma market is segmented into 2 categories: diagnosis and treatment.

The fibroadenoma market is segmented into hospitals & clinics, ambulatory surgical centers, and others based on the end user.

Regional Perspectives

In 2022, North America held the largest market share of over 38.49% due to the advanced diagnostic techniques, medical infrastructure, and reimbursement policies and insurance coverage. Additionally, North Americans are more cognizant of health concerns and have greater access to healthcare than other regions. Even in cases where fibroadenomas are asymptomatic, this results in more frequent exams and diagnoses.

The fibroadenoma market in Europe is expected to experience substantial growth during the forecast year, 2024-2032, because of the growing emphasis on minimally invasive procedures for fibroadenomas, such as cryoablation and vacuum-assisted excision, which are particularly prevalent in Europe. The region's hospitals and institutions are well-equipped to perform these procedures, which attract patients who are interested in less invasive alternatives.

The Asia-Pacific fibroadenoma market is the fastest-growing region during the forecast period because of the frequent introduction of breast diagnosis and treatment devices through expansion. IceCure Medical Ltd. announced in May 2023 that ProSense had been installed and inaugurated at Kovai Medical Center and Hospital ("KMCH") in India.

Major Players

GE Healthcare (US), Koninklijke Philips N.V. (Germany), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Canon Medical Systems Corporation (Japan), Dilon Technologies (US), Pfizer, Inc. (US), IceCure Medical (Israel), Alpinion Medical Systems (South Korea), and Fujifilm Holdings Corporation (Japan) are among the key companies in the fibroadenoma market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASED AWARENESS ABOUT FIBROADENOMA THROUGH PUBLIC EDUCATION CAMPAIGNS
  • 4.2.2 DEVELOPMENT OF IMPROVED DIAGNOSTIC TECHNIQUES TO ACCURATELY IDENTIFY FIBROADENOMA
  • 4.2.3 INCREASING PREVALENCE OF FIBROADENOMA AMONG WOMEN
• 4.3 RESTRAINTS
  • 4.3.1 HIGH COST OF TREATMENT OF FIBROADENOMA
• 4.4 OPPORTUNITY
  • 4.4.1 RESEARCH INTO NEW TREATMENT OPTIONS FOR FIBROADENOMA, SUCH AS MINIMALLY INVASIVE SURGICAL PROCEDURES OR MEDICATIONS
  • 4.4.2 GROWING ADOPTION OF MINIMALLY INVASIVE SURGICAL PROCEDURES FOR THE TREATMENT OF FIBROADENOMA
• 4.5 CHALLENGES
  • 4.5.1 NON-LIFE THREATENING NATURE OF FIBROADENOMAS
• 4.6 IMPACT ANALYSIS OF COVID-19
  • 4.6.1 IMPACT 0N OVERALL FIBROADENOMA INDUSTRY
    • 4.6.1.1 ECONOMIC IMPACT
  • 4.6.2 IMPACT ON GLOBAL FIBROADENOMA MARKET
  • 4.6.3 IMPACT ON THE SUPPLY CHAIN OF FIBROADENOMA
  • 4.6.4 IMPACT ON MARKET DEMAND OF FIBROADENOMA
    • 4.6.4.1 IMPACT DUE TO RESTRICTIONS/LOCKDOWN
    • 4.6.4.2 CONSUMER SENTIMENTS
  • 4.6.5 IMPACT ON PRICING OF FIBROADENOMA

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 RAW MATERIALS
  • 5.1.2 MANUFACTURING / PRODUCTION/ PROCESSING
  • 5.1.3 DISTRIBUTION CHANNEL
  • 5.1.4 END-USER
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 BARGAINING POWER OF SUPPLIERS
  • 5.2.2 BARGAINING POWER OF BUYERS
  • 5.2.3 THREAT OF NEW ENTRANTS
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL FIBROADENOMA MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 SIMPLE FIBROADENOMA
• 6.3 COMPLEX FIBROADENOMA

7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT

• 7.1 INTRODUCTION
• 7.2 DIAGNOSIS
  • 7.2.1 ULTRASOUND SCAN
  • 7.2.2 MAMMOGRAPHY
  • 7.2.3 BIOPSY
• 7.3 TREATMENT
  • 7.3.1 CRYOBLATION
  • 7.3.2 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU)
  • 7.3.3 LUMPECTOMY
  • 7.3.4 DRUGS
    • 7.3.4.1 DYDROGESTERONE
    • 7.3.4.2 MEDROXYPROGESTERONE
    • 7.3.4.3 SELECTIVE ESTROGEN RECEPTOR MODULATORS
    • 7.3.4.4 OTHERS

8 GLOBAL FIBROADENOMA MARKET, BY END-USER

• 8.1 INTRODUCTION
• 8.2 HOSPITAL AND CLINICS
• 8.3 DIAGNOSTIC CENTERS
• 8.4 OTHERS

9 GLOBAL FIBROADENOMA MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
  • 9.2.3 MEXICO
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 SPAIN
  • 9.3.5 ITALY
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 SOUTH AMERICA
  • 9.5.2 MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 COMPETITION DASHBOARD
• 10.3 MARKET SHARE ANALYSIS,
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.5.1 PRODUCT LAUNCH
  • 10.5.2 PARTNERSHIP
  • 10.5.3 EXPANSION

11 COMPANY PROFILES

• 11.1 GE HEALTHCARE
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGY
• 11.2 KONINKLIJKE PHILIPS N.V.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGY
• 11.3 SHIMADZU CORPORATION
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGY
• 11.4 SIEMENS HEALTHINEERS
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGY
• 11.5 CANON MEDICAL SYSTEMS CORPORATION
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 SWOT ANALYSIS
  • 11.5.5 KEY DEVELOPMENTS
  • 11.5.6 KEY STRATEGY
• 11.6 DILON TECHNOLOGIES
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 PRODUCTS OFFERED
  • 11.6.3 SWOT ANALYSIS
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGY
• 11.7 PFIZER, INC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGY
• 11.8 ICECURE MEDICAL
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGY
• 11.9 ALPINION MEDICAL SYSTEMS
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCTS OFFERED
  • 11.9.3 KEY DEVELOPMENTS
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 KEY STRATEGY
• 11.10 FUJIFILM HOLDINGS CORPORATION
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCTS OFFERED
  • 11.10.3 KEY DEVELOPMENTS
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 KEY STRATEGY

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 3 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY SIMPLE FIBROADENOMA, 2019-2032 (USD MLLION)
• TABLE 4 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY COMPLEX FIBROADENOMA, 2019-2032 (USD MLLION)
• TABLE 5 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 6 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2032 (USD MLLION)
• TABLE 7 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY TREATMENT, 2019-2032 (USD MLLION)
• TABLE 8 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 9 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY HOSPITAL AND CLINICS, 2019-2032 (USD MLLION)
• TABLE 10 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSTIC CENTERS, 2019-2032 (USD MLLION)
• TABLE 11 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY OTHERS, 2019-2032 (USD MLLION)
• TABLE 12 GLOBAL FIBROADENOMA MARKET, BY REGION, 2019-2032 (USD MLLION)
• TABLE 13 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 14 NORTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 15 NORTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 16 NORTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 17 US FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 18 US FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 19 US FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 20 CANADA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 21 CANADA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 22 CANADA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 23 MEXICO FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 24 MEXICO FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 25 MEXICO FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 26 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 27 EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 28 EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 29 EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 30 GERMANY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 31 GERMANY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 32 GERMANY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 33 FRANCE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 34 FRANCE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 35 FRANCE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 36 UK FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 37 UK FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 38 UK FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 39 SPAIN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 40 SPAIN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 41 SPAIN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 42 ITALY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 43 ITALY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 44 ITALY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 45 REST OF EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 46 REST OF EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 47 REST OF EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 48 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 49 ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 50 ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 51 ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 52 CHINA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 53 CHINA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 54 CHINA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 55 INDIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 56 INDIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 57 INDIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 58 JAPAN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 59 JAPAN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 60 JAPAN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 61 SOUTH KOREA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 62 SOUTH KOREA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 63 SOUTH KOREA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 64 AUSTRALIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 65 AUSTRALIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 66 AUSTRALIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 67 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 68 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 69 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 70 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
• TABLE 71 REST OF THE WORLD FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 72 REST OF THE WORLD FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 73 REST OF THE WORLD FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 74 SOUTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 75 SOUTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 76 SOUTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 77 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
• TABLE 78 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
• TABLE 79 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
• TABLE 80 PUBLIC PLAYERS STOCK SUMMARY
• TABLE 81 PRODUCT LAUNCH
• TABLE 82 PARTNERSHIP
• TABLE 83 EXPANSION
• TABLE 84 GE HEALTHCARE: PRODUCTS OFFERED
• TABLE 85 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
• TABLE 86 SHIMADZU CORPORATION: PRODUCTS OFFERED
• TABLE 87 SHIMADZU CORPORATION: KEY DEVELOPMENTS
• TABLE 88 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
• TABLE 89 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS
• TABLE 90 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED
• TABLE 91 CANON MEDICAL SYSTEMS CORPORATION: KEY DEVELOPMENTS
• TABLE 92 DILON TECHNOLOGIES: PRODUCTS OFFERED
• TABLE 93 DILON TECHNOLOGIES: KEY DEVELOPMENTS
• TABLE 94 PFIZER, INC: PRODUCTS OFFERED
• TABLE 95 ICECURE MEDICAL: PRODUCTS OFFERED
• TABLE 96 ALPINION MEDICAL SYSTEMS: PRODUCTS OFFERED
• TABLE 97 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 GLOBAL FIBROADENOMA MARKET: STRUCTURE
• FIGURE 2 GLOBAL FIBROADENOMA MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
• FIGURE 4 PORTER'S FIVE FORCES MODEL: GLOBAL FIBROADENOMA MARKET
• FIGURE 5 GLOBAL FIBROADENOMA MARKET, BY TYPE, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 6 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2022 (% SHARE)
• FIGURE 7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 8 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2022 (% SHARE)
• FIGURE 9 GLOBAL FIBROADENOMA MARKET, BY END-USER, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 10 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2022 (% SHARE)
• FIGURE 11 GLOBAL FIBROADENOMA MARKET, BY REGION, 2022 (% SHARE)
• FIGURE 12 NORTH AMERICA MARKET: COMPARATIVE ANALYSIS
• FIGURE 13 NORTH AMERICA MARKET: SWOT ANALYSIS
• FIGURE 14 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 15 EUROPE MARKET: COMPARATIVE ANALYSIS
• FIGURE 16 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 17 EUROPE MARKET: SWOT ANALYSIS
• FIGURE 18 ASIA PACIFIC MARKET: COMPARATIVE ANALYSIS
• FIGURE 19 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
• FIGURE 21 REST OF THE WORLD MARKET: COMPARATIVE ANALYSIS
• FIGURE 22 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
• FIGURE 23 REST OF THE WORLD MARKET: SWOT ANALYSIS
• FIGURE 24 COMPETITOR DASHBOARD: GLOBAL FIBROADENOMA MARKET
• FIGURE 25 GLOBAL FIBROADENOMA MARKET: COMPETITIVE ANALYSIS,
• FIGURE 26 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 27 GE HEALTHCARE: SWOT ANALYSIS
• FIGURE 28 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS
• FIGURE 29 SHIMADZU CORPORATION: SWOT ANALYSIS
• FIGURE 30 SIEMENS HEALTHINEERS: SWOT ANALYSIS
• FIGURE 31 CANON MEDICAL SYSTEMS CORPORATION: SWOT ANALYSIS
• FIGURE 32 DILON TECHNOLOGIES: SWOT ANALYSIS
• FIGURE 33 PFIZER, INC: SWOT ANALYSIS
• FIGURE 34 ICECURE MEDICAL: SWOT ANALYSIS
• FIGURE 35 ALPINION MEDICAL SYSTEMS: SWOT ANALYSIS